Has had an allogeneic tissue/solid organ transplant.
Prior allogeneic stem cell transplant or solid organ transplant
History of allogeneic bone marrow, stem-cell, or solid organ transplant
Prior allogeneic bone marrow or solid organ transplant
Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant
Any prior allogeneic hematopoietic stem cell or solid organ transplant.
Patients are not eligible if they have had or are planned for solid organ transplant or allogeneic hematopoietic stem cell transplant
Had a solid organ or allogeneic bone marrow transplant
Has had an allogeneic tissue/solid organ transplant
Previously received a solid organ transplant or allogeneic progenitor/stem cell transplant.
Prior allogeneic stem cell or solid organ transplant
Prior allogeneic stem cell or solid organ transplant
Prior allogeneic stem cell or solid organ transplant;
Solid organ or tissue transplant including stem cell transplant
Prior allogeneic transplant of any solid organ or bone marrow/stem cells
Has had an allogeneic tissue/solid organ transplant.
Prior allogeneic stem cell or solid organ transplant
Prior allogeneic stem cell or solid organ transplant
History of allogeneic tissue or solid organ transplant
History of allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant.
Prior allogeneic stem cell transplant or solid organ transplant
Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
Has had an allogeneic tissue/solid organ transplant
Prior allogeneic solid organ transplant
Patient with history of prior solid organ or allogeneic bone marrow transplant
Patients who have a history of an allogeneic tissue/solid organ transplant are not eligible
Has had an allogeneic tissue/solid organ transplant
History of solid organ or stem cell transplant requiring immunosuppressive medications
History of solid organ or stem cell transplant requiring immunosuppressive medications
Prior allogeneic stem cell transplant or solid organ transplant
Prior allogeneic stem cell or solid organ transplant
Prior allogeneic stem cell transplant or solid organ transplant
Prior allogeneic stem cell or solid organ transplant
Prior allogeneic bone marrow or solid organ transplant
History of allogeneic tissue/solid organ transplant
Prior allogeneic stem cell or solid organ transplant
History of allogeneic bone marrow, stem cell, or solid organ transplant
Has had an allogeneic tissue/solid organ transplant
Prior allogeneic stem cell or solid organ transplant
Prior allogeneic stem cell or solid organ transplant
Has had previous allogeneic tissue/solid organ transplant
History of allogeneic bone marrow, stem cell, or solid organ transplant
Prior allotransplant, including allogeneic hematopoietic cell transplant or solid organ allogeneic transplant
Prior solid organ or stem cell transplant
Prior allogeneic stem cell or solid organ transplant
Has previously had a hematopoetic stem cell transplant or solid organ transplant
Participants with prior allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
History of allogeneic stem-cell (or other organ) transplantation
Prior allogeneic stem cell or solid organ transplantation;
Prior allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
History of solid organ or stem cell transplantation
Prior allogeneic stem cell or solid organ transplantation.
Prior allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Receipt of any organ transplantation including autologous or allogeneic stem-cell transplantation.
Prior allogeneic stem cell or solid organ transplantation
Prior allogenic stem cell or solid organ transplantation
Patients with prior allogeneic stem cell or solid organ transplantation.
Receipt of any organ transplantation including allogeneic stem-cell transplantation.
Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant).
History of organ transplantation (e.g. stem cell or solid organ transplant)
Receipt of any organ transplantation, including allogeneic stem-cell transplantation, except of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant)
Prior allogeneic stem cell or solid organ transplantation
For cohort 1 (DLBCL) only: prior organ transplantation including allogeneic stem-cell transplantation
Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant).
Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years
Prior allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Prior organ transplantation, including allogeneic stem cell transplantation
Prior allogeneic stem cell or organ transplantation including corneal transplant
Prior allogeneic stem cell or solid organ transplantation
Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g. corneal transplant, hair transplant)
History of solid organ or stem cell transplantation
Prior organ transplantation including allogeneic stem cell transplantation, brain metastases (except those meeting certain protocol specified criteria which are acceptable), significant acute or chronic infections, a history of cardiovascular/cerebrovascular disease.
History of allogeneic stem?cell (or other organ) transplantation
Prior organ transplantation including allogeneic stem cell transplantation
Participants with prior allogeneic stem cell or solid organ transplantation
Prior organ transplantation including allogeneic stem-cell transplants
Prior organ transplantation including allogeneic stem-cell transplantation
Prior organ transplantation, including allogeneic stem cell transplantation
Prior organ transplantation, including allogeneic stem cell transplantation
Patients with a prior history of allogeneic stem cell or solid organ transplantation
Receipt of any organ transplantation including allogeneic stem-cell transplantation
Patients with prior stem cell transplantation or solid organ transplantation.
Patients with prior allogeneic stem cell or solid organ transplantation
Have undergone organ transplantation including allogeneic or autologous stem-cell transplantation, at any time;
Patients with history of organ and allogeneic stem cell transplantation
Previous history of autologous or allogeneic blood stem cell transplantation or solid organ transplantation
History of allogeneic stem cell transplantation, prior solid organ transplant, or anticipated to undergo solid organ transplantation, or left ventricular assist device (LVAD) implantation, during the course of the study.
Patients with prior stem cell transplantation or solid organ transplantation.
Patients with a prior history of allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Prior stem cell transplantation or solid organ transplantation
History of organ or previous autologous/allogeneic stem cell transplantation
Prior allogeneic stem cell or solid organ transplantation
Prior organ transplantation, including allogeneic stem-cell transplantation
Has undergone prior organ or allogeneic hematopoetic stem cell transplantation
Prior allogeneic stem cell or solid organ transplantation
Subjects has history of organ or allogeneic stem cell transplantation
Prior allogeneic stem cell or solid organ transplantation
Has undergone prior organ or allogeneic hematopoetic stem cell transplantation
Prior allogeneic hematopoietic stem-cell transplantation or prior solid-organ transplantation
Prior organ transplantation, including allogeneic stem-cell transplantation
Prior allogeneic stem cell or solid organ transplantation
History of allogeneic stem cell or solid organ transplantation
Receipt of any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (eg, corneal transplant, hair transplant)
Prior organ transplantation, including allogeneic stem cell transplantation
Participants with prior allogeneic stem cell or solid organ transplantation
Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation
Receipt of any organ transplantation, including allogeneic stem-cell transplantation.
history of allogeneic stem cell or solid organ transplantation.
Prior allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
History of myelodysplastic syndrome, allogeneic stem cell or solid organ transplantation
History of allogeneic stem-cell (or other organ) transplantation
Prior organ transplantation including allogeneic stem-cell transplantation
History of prior allogeneic hematopoietic stem cell transplantation or prior solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Prior allogeneic stem cell or solid organ transplantation
Patients who have previously received a prior organ transplantation, including allogeneic stem cell transplantation
Prior organ transplantation, including allogeneic stem cell transplantation
Prior organ transplantation, including allogeneic stem cell transplantation
Prior allogeneic stem cell or solid organ transplantation
Participants with prior allogeneic stem cell or solid organ transplantation
Patients who previously received a solid organ transplant
Patients with any history of solid organ or bone marrow transplant will not be eligible
Previous HCT or solid organ transplant.
Organ transplant recipients other than bone marrow transplant
Prior solid organ transplant
Patients scheduled for a combined transplant (such as liver-kidney), or having a previous solid organ, bone marrow, or autologous islet cell transplant.
Prior solid organ or hematologic transplant.
Organ transplant recipients
History of major solid organ transplant (i.e., heart, lungs, liver and kidney).
EXCLUSION - PROCUREMENT: History of solid organ transplant
EXCLUSION - INFUSION: History of solid organ transplant
Prior solid organ transplant.
Organ transplant
History of prior solid organ or bone marrow transplant
Prior solid organ transplant
M1c disease (solid organ metastasis)
Organ transplant recipient
Any solid organ transplant or bone marrow transplant
Had a solid organ or hematologic transplant.
Has had a prior solid organ transplant.
Prior organ transplant requiring immunosuppressive therapy.
Participants that have had bone marrow or solid organ transplant are excluded.
Patients who have undergone a bone marrow or solid organ transplant
Had a solid organ or hematologic transplant
Subjects who have had solid organ transplant
Receipt of solid organ transplant
History of allogeneic organ transplant (e.g. solid organ/bone marrow transplant patients)
Patients with a history of solid organ transplant
Had a solid organ or hematologic transplant
Had a solid organ or hematologic transplant
Prior solid organ transplant
Patients with previous solid organ transplant
Malignancy attributed to prior solid organ transplant
Prior solid organ transplant requiring immunosuppressive therapy
Prior organ transplant requiring immunosuppressive therapy
Prior solid organ transplant
History of organ transplant requiring therapeutic immunosuppression
History of solid organ transplant
History of immunodeficiency, solid organ transplant, or tuberculosis
Has a history of a bone marrow or solid organ transplant.
Previous organ transplant
Prior organ transplant requiring immunosuppressive therapy
Solid organ transplant
Has had a solid organ or hematologic transplant.
Has had a prior solid organ transplant.
Has had a prior solid organ transplant.
Organ transplant recipients other than bone marrow transplant;
Other immunocompromised status (e.g. organ transplant)
Status post solid organ transplant.
Patient has received an organ transplant
Had a solid organ or hematologic transplant
Undergone a bone marrow or solid organ transplant.
Previous organ transplant
Prior organ transplant requiring immunosuppressive therapy
Subject has received an organ transplant
Patients who have previously received a solid organ transplant are not eligible
Prior bone marrow transplant or history of organ transplant requiring the need for any chronic immunosuppressive medications
Previous organ transplant
History of any organ or bone marrow transplant
Prior solid organ transplant
Planned organ transplant during the study
Prior organ transplant requiring immunosuppressive therapy
Undergone a liver or other organ transplant
Subjects who have received any type of solid organ transplant
Patients who have undergone hematopoietic cell transplant (HCT), solid organ transplant (SOT)
Patients with known HIV or with solid organ transplant
History of solid organ transplant or bone marrow transplant
Patients who have received organ transplant
Single solid organ recipients (kidney only)
Organ transplant recipient
History of organ transplant requiring therapeutic immunosuppression
Subjects with a previous solid organ transplant
History (hx) of organ transplant
Organ Transplant: Patients may NOT be the recipients of an organ transplant.
GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have had a prior solid organ transplant are not eligible
Prior organ transplant
Received solid organ transplant (kidney or other)
Single solid organ recipient (kidney only)
Prior solid organ or bone marrow transplant
Subjects who have received any type of solid organ transplant
Prior organ transplant
History of allogenic bone marrow or solid organ transplant
Autologous or allogenic transplant within the 60 days prior to Cycle 1 Day 1.
Has had an allogenic tissue/sold organ transplant.
History of autologous/allogenic bone marrow transplant.
Previous allogenic bone marrow transplant.
Subjects with a history of autologous or allogenic stem cell transplantation must have adequate peripheral blood counts independent of any growth factor support, and have recovered from any transplant related toxicity(s) and be at least 100 days post-autologous transplant prior to first dose of study drug or at least 6 months post-allogenic transplant prior to first dose of study drug and not have active graft-versus-host disease (GVHD), i.e., requiring treatment.
Prior organ transplant including allogenic hematopoietic stem cell transplant
Prior allogenic stem cell or solid organ transplant
Autologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant
Prior allogenic transplant
Has allogenic haemopoietic stem cell (HSC) transplant.
Has had an allogenic tissue/solid organ transplant
History of allogenic transplant
History of allogenic transplant
Autologous or allogenic transplant within the 60 days prior to Screening.
Eligible for allogenic or autologous stem cell transplant
Patients within 60 days of allogenic bone transplant are not eligible; patients with solid organ transplant are not eligible
Autologous or allogenic transplant within the 60 days prior to the Screening visit.
Allogenic tissue/solid organ transplant
History of allogenic organ transplant.
History of an autologous/allogenic bone marrow transplant.
Undergone an allogenic stem cell transplant
Subjects with a history of autologous or allogenic stem cell transplant must have adequate bone marrow independent of any growth factor support, and have recovered from any transplant related toxicity(s); and either greater than 100 days post-autologous transplant (prior to first dose of study drug) or greater than or equal to 6 months post-allogenic transplant (prior to first dose of study drug) and not have active graft-versus-host disease (i.e., requiring treatment).
Have previously received an allogenic stem cell transplant
Receipt of allogenic or autologous stem cell transplant
More than 2 months out from allogenic hematopoietic stem cell transplant prior to randomization.
Previous allogenic hematopoietic transplant within 90 d
History of allogenic organ transplant
Prior allogenic stem cell or solid organ transplant
Has previously received an allogenic hematopoietic stem cell transplant.
Prior allogenic stem cell or solid organ transplant
Autologous or allogenic transplant within the 60 days prior to Screening.
cHL COHORT ONLY: history of allogeneic transplant
Previous allogeneic bone marrow transplant
Patients with previous allogeneic bone marrow transplant
Prior allogeneic transplant
Previous allogeneic transplant
Subject with a history of organ transplant or allogeneic bone marrow transplant;
Prior allogeneic transplant
Has received an allogeneic bone marrow or allogeneic stem cell transplant.
History of an allogeneic bone marrow transplant.
Prior allogeneic bone marrow transplant.
Participants who have received a previous allogeneic bone marrow transplant
Participant has had a prior allogeneic transplant.
Subjects with clinically significant cardiovascular disease, history of organ transplant or allogeneic bone marrow transplant, active known or history of autoimmune disease that might recur or major surgery within 28 days prior to the first dose or still recovering from prior surgery.
Participants who are within 6 months of an allogeneic bone marrow transplant
the subject has recovered from transplant-associated toxicities prior to the first dose of GSK525762, and For subjects with a prior history of allogeneic transplant,
Clinically significant pulmonary dysfunction, active infection, prior allogeneic bone marrow transplant, active autoimmune disease
Prior allogeneic transplant if performed < 6 months prior to first dose of AMV564, if patient has active GVHD, or if patient has not been off immunosuppressive
Previous allogeneic transplant
Prior allogeneic bone marrow transplant within 12 months of screening date
Prior allogeneic transplant, within the last 5 years
We will exclude patients who are eligible for an allogeneic bone marrow transplant at the time of study enrollment; if an enrolled patient subsequently becomes eligible for transplant, they will not be prevented from proceeding to the appropriate clinical treatment indicated
FOR ALL PHASES (Ib AND II): History of having received an allogeneic bone marrow or organ transplant
Previous allogeneic bone marrow transplant
Prior allogeneic bone marrow transplant
Prior allogeneic transplant
Prior allogeneic transplant
Willingness to have an allogeneic transplant
Have undergone a prior allogeneic bone marrow transplant (BMT)
PART 1: History of prior allogeneic transplant
History of an allogeneic solid organ transplant or bone marrow transplant, or current active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
Allogeneic transplant with a human leukocyte antigen (HLA)-identical sibling will be recommended for patients < 55 years; if the patient refuses allogeneic transplant, they may still be eligible for this protocol
Prior allogeneic transplant
Patients with secondary AML, and patients with a prior autologous and allogeneic bone marrow transplant are eligible
Subject has a history of organ transplant or allogeneic bone marrow transplant;
Receipt of an allogeneic bone marrow or allogeneic stem cell transplant
Patients who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than 12 months prior to initiation of study
Has a transplanted organ or has undergone allogeneic bone marrow transplant
Patients eligible, at the time of starting treatment, for curative therapeutic approaches (such as allogeneic transplant) are not eligible for the trial; however, patients who achieve CR or partial response (PR) as a result of therapy on this trial may proceed to allogeneic transplant
Prior allogeneic transplant
Prior allogeneic bone marrow transplant
Patients with an organ transplant, including those that have received an allogeneic bone marrow transplant.
History of having received an allogeneic bone marrow or organ transplant
History of an allogeneic solid organ transplant or bone marrow transplant, or current active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.
Previous allogeneic bone marrow transplant.
Prior allogeneic transplant of any kind
Eligible for allogeneic transplant in the treating physicians’ judgment and by institutional standards
Previously received an allogeneic transplant
Autologous or allogeneic bone marrow transplant as second-line therapy.
Prior allogeneic transplant
Prior allogeneic transplant
> 60 days after reduced intensity conditioning (RIC) allogeneic transplant for lymphoma
Prior allogeneic transplant
Has received an allogeneic bone marrow or allogeneic stem cell transplant.
Eligible for allogeneic bone marrow transplant.
Receipt of an allogeneic transplant.
No more than 4 prior lines of systemic anti-cancer therapy and no prior bone marrow transplant or stem cell transplant within 12 months of dosing, and no prior allogeneic transplant.
Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
Previously received an allogeneic transplant.
Any prior allogeneic transplant.
Allogeneic transplant recipients undergoing ablative transplants will also be eligible to participate; those receiving nonablative regimens (a small proportion of allogeneic transplant recipients at UWCCC) will be excluded
Patients who have failed a prior autologous or allogeneic transplant are eligible; however, at least 6 months must have elapsed between the start of this reduced intensity conditioning regimen and the last transplant if patient had a prior autologous or myeloablative allogeneic bone marrow transplant (BMT)
Prior allogeneic transplant
Underwent a previous related or unrelated allogeneic transplant
Prior allogeneic transplant
Prior allogeneic transplant
Patients who have received a prior allogeneic transplant will be excluded
Subject has had prior allogeneic transplant.
Has received an allogeneic transplant in the past; scheduled to receive a second allogeneic transplant
Prior allogeneic BMT
Prior solid organ or bone marrow progenitor cell transplantation.
History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
History of solid organ, allogeneic bone marrow, or stem cell transplantation within the 6 months prior to consent.
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation.
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
Prior solid organ or bone marrow progenitor cell transplantation.
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
History of solid organ, bone marrow, or progenitor cell transplantation
Prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation
History of prior allogeneic bone marrow/stem-cell or solid organ transplantation.
